Corcept Therapeutics Incorporated (NASDAQ:CORT) Director Sells $149,776.00 in Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT) Director Daniel N. Swisher, Jr. sold 2,200 shares of the company’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $68.08, for a total value of $149,776.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Daniel N. Swisher, Jr. also recently made the following trade(s):

• On Friday, January 10th, Daniel N. Swisher, Jr. sold 2,200 shares of Corcept Therapeutics stock. The shares were sold at an average price of $50.54, for a total value of $111,188.00.
• On Tuesday, December 10th, Daniel N. Swisher, Jr. sold 2,200 shares of Corcept Therapeutics stock. The shares were sold at an average price of $59.46, for a total value of $130,812.00.

Corcept Therapeutics Trading Down 1.2 %

CORT stock opened at $72.72 on Friday. The firm has a market cap of $7.62 billion, a P/E ratio of 57.71 and a beta of 0.58. Corcept Therapeutics Incorporated has a 1-year low of $20.84 and a 1-year high of $74.61. The business’s 50 day moving average is $57.97 and its 200-day moving average is $49.31. The company has a current ratio of 3.70, a quick ratio of 3.64 and a debt-to-equity ratio of 0.01.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. Canaccord Genuity Group upped their price target on Corcept Therapeutics from $78.00 to $130.00 and gave the company a “buy” rating in a report on Thursday, January 30th. StockNews.com lowered Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 25th. HC Wainwright reiterated a “buy” rating and issued a $80.00 price objective on shares of Corcept Therapeutics in a research note on Friday, February 7th. Finally, Sandler O’Neill reiterated a “buy” rating on shares of Corcept Therapeutics in a research note on Friday, October 18th. Six analysts have rated the stock with a buy rating, According to MarketBeat, Corcept Therapeutics has a consensus rating of “Buy” and a consensus target price of $88.25.

Institutional Investors Weigh In On Corcept Therapeutics

A number of large investors have recently bought and sold shares of CORT. Capital Performance Advisors LLP bought a new stake in Corcept Therapeutics during the 3rd quarter worth approximately $25,000. Kestra Investment Management LLC bought a new stake in Corcept Therapeutics during the 4th quarter worth approximately $27,000. Canada Pension Plan Investment Board bought a new stake in Corcept Therapeutics during the 4th quarter worth approximately $40,000. National Bank of Canada FI bought a new stake in Corcept Therapeutics during the 4th quarter worth approximately $42,000. Finally, USA Financial Formulas bought a new stake in Corcept Therapeutics during the 4th quarter worth approximately $54,000. 93.61% of the stock is currently owned by institutional investors.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.